These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 34591258)
1. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine. Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial. Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773 [TBL] [Abstract][Full Text] [Related]
3. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile. Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial. Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782 [TBL] [Abstract][Full Text] [Related]
5. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906 [TBL] [Abstract][Full Text] [Related]
6. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine. Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial. Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214 [TBL] [Abstract][Full Text] [Related]
8. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Read RC; Baxter D; Chadwick DR; Faust SN; Finn A; Gordon SB; Heath PT; Lewis DJ; Pollard AJ; Turner DP; Bazaz R; Ganguli A; Havelock T; Neal KR; Okike IO; Morales-Aza B; Patel K; Snape MD; Williams J; Gilchrist S; Gray SJ; Maiden MC; Toneatto D; Wang H; McCarthy M; Dull PM; Borrow R Lancet; 2014 Dec; 384(9960):2123-31. PubMed ID: 25145775 [TBL] [Abstract][Full Text] [Related]
9. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122 [TBL] [Abstract][Full Text] [Related]
10. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM; Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281 [TBL] [Abstract][Full Text] [Related]
12. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD; BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030 [TBL] [Abstract][Full Text] [Related]
13. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB. Bekkat-Berkani R; Fragapane E; Preiss S; Rappuoli R; Sohn WY; Soumahoro L; Vadivelu K J Infect; 2022 Nov; 85(5):481-491. PubMed ID: 36087745 [TBL] [Abstract][Full Text] [Related]
14. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. Zambrano B; Peterson J; Deseda C; Julien K; Spiegel CA; Seyler C; Simon M; Hoki R; Anderson M; Brabec B; Áñez G; Shi J; Pan J; Hagenbach A; Von Barbier D; Varghese K; Jordanov E; Dhingra MS Pediatr Res; 2023 Sep; 94(3):1035-1043. PubMed ID: 36899125 [TBL] [Abstract][Full Text] [Related]
15. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults. Lee HJ; Chung MH; Kim WJ; Hong YJ; Choi KM; Lee J; Oh CE; Welsch JA; Kim KH; Hong KB; Dagnew AF; Bock H; Dull PM; Odrljin T Int J Infect Dis; 2014 Nov; 28():204-10. PubMed ID: 25316331 [TBL] [Abstract][Full Text] [Related]
17. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods. Klein NP; Block SL; Essink B; Barbi S; Smolenov I; Keshavan P Vaccine; 2019 Jul; 37(32):4460-4467. PubMed ID: 31279564 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Kimura A; Toneatto D; Kleinschmidt A; Wang H; Dull P Clin Vaccine Immunol; 2011 Mar; 18(3):483-6. PubMed ID: 21177912 [TBL] [Abstract][Full Text] [Related]
19. MenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults. Tipton M; Daly W; Senders S; Block SL; Lattanzi M; Mzolo T; Barbi S; Pellegrini M; Keshavan P Vaccine; 2019 Sep; 37(42):6171-6179. PubMed ID: 31495595 [TBL] [Abstract][Full Text] [Related]
20. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]